Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

Jasmohan S. Bajaj, Douglas M. Heuman, Arun J. Sanyal, Phillip B. Hylemon, Richard K. Sterling, R. Todd Stravitz, Michael Fuchs, Jason M. Ridlon, Kalyani Daita, Pamela Monteith, Nicole A. Noble, Melanie B. White, Andmorgan Fisher, Masoumeh Sikaroodi, Huzefa Rangwala, Patrick M. GillevetPLoS 2013 · DOI

Abstract

Minimal Hepatic Encephalopathy (MHE) is a subclinical cognitive impairment in cirrhosis patients driven by a dysfunctional gut-liver-brain axis. While rifaximin is a standard treatment, its mechanism of action remains poorly understood. This study (ClinicalTrials.gov NCT01069133) uses a systems biology approach to demonstrate that rifaximin improves cognitive function not by drastically reducing gut bacteria, but by "rewiring" the metabolic crosstalk between the microbiome and the host, shifting the environment toward a beneficial metabolic profile rich in brain-healthy fatty acids.

Introduction

Patients with advanced cirrhosis often develop Minimal Hepatic Encephalopathy (MHE), where gut-derived toxins like ammonia and endotoxins impair brain function. The gut-selective antibiotic rifaximin is effective in treating MHE, yet traditional culture-based methods have failed to explain its efficacy. This research sought to understand how rifaximin modulates the metabiome—the complex network of interactions between microbial communities and host metabolites—using modern "omics" and network analysis.

Methods

An open-label trial was conducted with 20 cirrhotic patients diagnosed with MHE. Participants received 550 mg of rifaximin twice daily for eight weeks. The study employed a multi-modal systems biology assessment:

  • Cognitive Testing: A battery of seven psychometric tests to measure mental processing and motor skills.
  • Microbiome Analysis: Multi-tagged pyrosequencing of fecal DNA to identify bacterial taxa.
  • Metabolomics: GC/LC-MS profiling of serum and urine metabolites.
  • Network Analysis: Correlation Difference (CorrDiff) networks to visualize changes in bacteria-metabolite relationships.
Figure 1: Patient enrollment and study flow diagram showing the progression from assessment to analysis for the 20-patient cohort.

Results

Cognitive and Clinical Improvements

Patients showed significant improvement in 6 out of 7 cognitive tests ($p < 0.01$). Systemic inflammation also decreased, with serum endotoxin levels dropping from 0.55 to 0.48 Eu/ml ($p = 0.02$).

Microbiome Stability vs. Metabolic Rewiring

Contrary to the traditional "bacterial killer" hypothesis, rifaximin caused almost no change in the overall abundance of gut bacteria. Principal Coordinates Analysis (PCO) and taxonomic pie charts revealed a stable core microbiome before and after treatment.

Figure 2: Fecal microbiome composition and PCO analysis showing minimal shifts in bacterial abundance and significant overlap in community structure before and after rifaximin treatment.

The clinical benefit instead stems from changing the interactions within the network. Post-treatment, global correlation networks became less complex and decentralized. Pathogenic taxa, such as Enterobacteriaceae, shifted their metabolic associations away from markers of oxidative stress and ammonia toward more neutral or beneficial associations.

The Fatty Acid Boost

A key finding was a significant increase in serum long-chain fatty acids (e.g., linoleic and arachidonic acid) post-treatment. These lipids are essential for brain health and neurogenesis, suggesting a direct link between gut modulation and cognitive recovery.

Discussion

This study suggests that rifaximin acts as a "modulator" of bacterial behavior and virulence rather than a broad-spectrum antibiotic. By simplifying metabolic conversations and boosting neuroprotective lipids, it effectively treats MHE without disrupting the core microbiome.

Limitations: The study's small sample size (N=20) and the presence of unidentified metabolites in current databases suggest areas for further research. Future studies using metatranscriptomics could further elucidate the specific bacterial pathways activated or suppressed by rifaximin to improve cognitive outcomes.

Summary updated

Abstract

ClinicalTrials.gov NCT01069133.
BibTeX
@inproceedings{bajaj2013modulation,
  author = {Jasmohan S. Bajaj and Douglas M. Heuman and Arun J. Sanyal and Phillip B. Hylemon and Richard K. Sterling and R. Todd Stravitz and Michael Fuchs and Jason M. Ridlon and Kalyani Daita and Pamela Monteith and Nicole A. Noble and Melanie B. White and Andmorgan Fisher and Masoumeh Sikaroodi and Huzefa Rangwala and Patrick M. Gillevet},
  title = {{Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy}},
  booktitle = {PLoS},
  year = {2013},
  doi = {10.1371/journal.pone.0060042},
}
Figure